-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $148

Benzinga·07/07/2026 16:20:33
Listen to the news
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $142 to $148.